EUCAST News

EUCAST News

Here you can find the latest news and updates from EUCAST.

05 Nov 2021
Several public consultations - deadline 15 November 2021

There are several public consultations which will expire 15 November, 2021. Vibrio species - genral consultationon EUCAST clinical breakpoints for five species pathogenic to man(1 October - 15 November). Queries on...[more]

05 Nov 2021
Itraconazole rationale document updated

The two rationale documents on itraconazole (Candida spp and Aspergillus spp) were amalgamated and updated as Itraconazole rationale document v 3.0 (2021),[more]

18 Oct 2021
EUCAST on "intrinsic resistance and unusual phenotypes" updated

The EUCAST document Advice on intrinsic resistance and exceptional phenotypes v 3.3has been updated 18 October, 2021.[more]

06 Oct 2021
General consultation on colistin breakpoints

EUCAST is proposing to change colistin breakpoints to breakpoints in brackets. The consultation is open for comments between 6 October - 15 November. In breakpoint table v 12.0 (2022), EUCAST aims to introduce brackets for...[more]

04 Oct 2021
Seminar on EUCAST Disk diffusion of anaerobic bacteria 9 December

Disk diffusion of anaerobic bacteria in 16-20 hours (9 December, 2021; at 8AM, 1PM and 4PM CET to satisfy different time zones; link below). EUCAST has developed a disk diffusion method for AST of 5 anaerobic species (Bacteroides...[more]

04 Oct 2021
General consultation on breakpoints for anaerobic bacteria

EUCAST general and public consultation on breakpoints for anaerobic bacteria. Theconsultation pertains to the clinical breakpoints for Bacteroides spp., Prevotella spp., Fusobacterium necrophorum, Clostridium perfringens...[more]

30 Sep 2021
General consultation on clinical breakpoints for Vibrio species

General consultation on clinical breakpoints for Vibrio species 1 October - 15 November. Use the form available on the consultation webpage to comment. Queries can be addressed to gunnar.kahlmeter@eucast.org.[more]

Displaying results 15 to 21 out of 50

Archive